Molecule: Replication-deficient Simian Adenoviral Vector Vaccine

Vaccine

Research Institution

University of Oxford

Description

We have developed a replication-deficient simian adenoviral vector vaccine expressing the SARS-CoV-2 surface Spike protein (ChAdOx1 nCoV-19). Small scale GMP manufacture is in progress (at UOXF), with Phase I/II trials in Oxford due to initiate shortly. Process Development work for larger scale manufacture is also in progress.

Research Team

Andrew Pollard

Professor of Paediatric Infection and Immunity

University of Oxford

Adrian Hill

Professor of Human Genetics

University of Oxford

Sarah Gilbert

Head of Vaccine Development

University of Oxford

Teresa Lambe

Senior Scientist

University of Oxford

Sandy Douglas

Head of Sporozoite-targeting Malaria & Rabies Vaccines

University of Oxford

Project Details

Funding Sources

Funding in place from UKRI, NIHR, CEPI and CIFMS (CAMS Innovation fund for medical sciences).

Project Phases

Phase I/II testing for safety and immunogenicity,
Phase II/III testing for efficacy.
Large scale GMP manufacture
Additional funding will be required for full programme to be carried out

Planned Time to Trials

< 6 Months

Additional Resources

Needs

Hover for more information.

Funding

Partnerships

Expert Advice

Get In Touch

Directly connect with the responsible researchers by sending a message.

Thank you! Your message has been received and will be forwarded to the research team!

Oops! Something went wrong while submitting the form.